- Home
- IBTA vs TSHA Comparison
IBTA vs TSHA Comparison
Compare IBTA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- TSHA
- Stock Information
- Founded
- IBTA 2011
- TSHA 2019
- Country
- IBTA United States
- TSHA United States
- Employees
- IBTA N/A
- TSHA N/A
- Industry
- IBTA
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- TSHA Health Care
- Exchange
- IBTA Nasdaq
- TSHA Nasdaq
- Market Cap
- IBTA 892.4M
- TSHA 728.4M
- IPO Year
- IBTA 2024
- TSHA 2020
- Fundamental
- Price
- IBTA $37.62
- TSHA $2.76
- Analyst Decision
- IBTA Buy
- TSHA Strong Buy
- Analyst Count
- IBTA 10
- TSHA 6
- Target Price
- IBTA $74.60
- TSHA $8.17
- AVG Volume (30 Days)
- IBTA 333.1K
- TSHA 2.7M
- Earning Date
- IBTA 08-13-2025
- TSHA 08-11-2025
- Dividend Yield
- IBTA N/A
- TSHA N/A
- EPS Growth
- IBTA 24.66
- TSHA N/A
- EPS
- IBTA 2.03
- TSHA N/A
- Revenue
- IBTA $369,501,000.00
- TSHA $7,224,000.00
- Revenue This Year
- IBTA $6.89
- TSHA N/A
- Revenue Next Year
- IBTA $15.55
- TSHA N/A
- P/E Ratio
- IBTA $18.12
- TSHA N/A
- Revenue Growth
- IBTA 7.20
- TSHA N/A
- 52 Week Low
- IBTA $31.40
- TSHA $1.05
- 52 Week High
- IBTA $79.80
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- TSHA 53.78
- Support Level
- IBTA N/A
- TSHA $2.53
- Resistance Level
- IBTA N/A
- TSHA $2.81
- Average True Range (ATR)
- IBTA 0.00
- TSHA 0.15
- MACD
- IBTA 0.00
- TSHA 0.01
- Stochastic Oscillator
- IBTA 0.00
- TSHA 60.22
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.